Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

CHRS

Coherus Biosciences Inc

Jun 14 • 04:00PM ET

1.69

Dollar change -0.09
Percentage change -5.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO SCHA VTWO VHT IWC IWN

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.79	Insider Own	4.53%	Shs Outstand	112.22M	Perf Week	0.00%
Market Cap	193.89M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	0.00%	Shs Float	109.53M	Perf Month	-22.48%
Income	-59.29M	PEG	-	EPS next Q	-0.32	Inst Own	70.01%	Short Float	20.14%	Perf Quarter	-23.87%
Sales	301.87M	P/S	0.64	EPS this Y	91.43%	Inst Trans	-1.48%	Short Ratio	11.65	Perf Half Y	-28.69%
Book/sh	-0.72	P/B	-	EPS next Y	-6.17%	ROA	-10.17%	Short Interest	22.06M	Perf Year	-68.47%
Cash/sh	2.26	P/C	0.75	EPS next 5Y	-	ROE	-	52W Range	1.43 - 5.48	Perf YTD	-49.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.73%	ROI	-26.65%	52W High	-69.16%	Beta	0.60
Dividend TTM	-	Quick Ratio	1.05	Sales past 5Y	-2.24%	Gross Margin	39.78%	52W Low	18.17%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.17	EPS Y/Y TTM	79.87%	Oper. Margin	-56.53%	RSI (14)	36.66	Volatility	5.75% 5.46%
Employees	306	Debt/Eq	-	Sales Y/Y TTM	64.63%	Profit Margin	-19.64%	Recom	1.67	Target Price	8.33
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	185.78%	Payout	-	Rel Volume	0.98	Prev Close	1.78
Sales Surprise	-5.68%	EPS Surprise	427.29%	Sales Q/Q	137.58%	Earnings	May 09 AMC	Avg Volume	1.89M	Price	1.69
SMA20	-10.46%	SMA50	-18.04%	SMA200	-36.98%	Trades		Volume	1,865,220	Change	-5.06%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15
Aug-08-17	Reiterated	JP Morgan	Overweight	$32 → $25
Jun-13-17	Reiterated	Maxim Group	Buy	$44 → $40
May-05-17	Initiated	BMO Capital Markets	Outperform	$54
Oct-19-16	Initiated	Robert W. Baird	Outperform	$40

Show Previous Ratings

Jun-05-24 09:00AM	Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors (GlobeNewswire)
May-30-24 09:00AM	Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 05:51PM	Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
09:00AM	Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA (GlobeNewswire)
May-13-24 09:23AM	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating (MT Newswires) +10.00%
04:45PM	Loading…
May-10-24 04:45PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -10.38%
May-09-24 05:15PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:30AM	Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan (GlobeNewswire)
May-08-24 09:00AM	Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer (GlobeNewswire)
May-01-24 04:30PM	Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +5.10%
Apr-24-24 10:02AM	Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.34%
Apr-08-24 08:30AM	Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting (GlobeNewswire)
Mar-16-24 03:35PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:28PM	Loading…
Mar-14-24 06:28PM	Why Coherus Biosciences Stock Tumbled on Thursday (Motley Fool) -5.65%
07:15AM	Q4 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:32PM	Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ... (GuruFocus.com)
04:13PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 (GlobeNewswire)
Mar-04-24 01:00AM	Coherus Completes Divestiture of Ophthalmology Franchise (GlobeNewswire) -5.81%
Feb-23-24 05:33PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Feb-21-24 08:30AM	Coherus Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire)
Feb-06-24 05:16PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +14.85%
Feb-05-24 08:00AM	Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP (GlobeNewswire)
Jan-23-24 11:37AM	Why Coherus BioSciences Stock Is Sinking Today (Motley Fool) -6.98%
Jan-22-24 03:41PM	Why Coherus Biosciences Popped Today (Motley Fool) +5.74%
08:38AM	Why Is Coherus BioSciences (CHRS) Stock Up 17% Today? (InvestorPlace)
01:15AM	Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal (GlobeNewswire)
04:05PM	Loading…
Jan-18-24 04:05PM	Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium (GlobeNewswire)
Jan-12-24 03:06AM	Here's Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS) (Insider Monkey)
Jan-04-24 08:00AM	INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI (toripalimab-tpzi) (PR Newswire)
Jan-03-24 09:00AM	Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 08:29AM	Coherus Announces U.S. Launch of LOQTORZI (GlobeNewswire) -5.71%
Dec-28-23 03:45PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +20.45%
11:07AM	Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody (Zacks)
Dec-27-23 05:07PM	These Stocks Moved the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com) +23.39%
01:06PM	These Stocks Are Moving the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com)
Dec-26-23 04:01PM	Coherus Announces FDA Approval of UDENYCA ONBODY , a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire) +7.92%
Dec-24-23 09:45AM	2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street (Motley Fool)
Dec-22-23 05:00PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Dec-11-23 08:30AM	Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx (GlobeNewswire)
Dec-07-23 05:55PM	Coherus BioSciences Announces CFO Transition Plans (GlobeNewswire)
Dec-06-23 04:00AM	Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-28-23 11:16AM	Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association (GlobeNewswire) +8.76%
Nov-10-23 03:15PM	Why Coherus BioSciences Was Plummeting This Week (Motley Fool)
Nov-07-23 03:37PM	Why Coherus Biosciences Stock Dropped Today (Motley Fool) -30.23%
10:46AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:19AM	Q3 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:13PM	Coherus BioSciences Inc (CHRS) Reports 27% Rise in Q3 2023 Net Revenue (GuruFocus.com)
04:43PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:07PM	Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-03-23 08:30AM	Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) +8.73%
Nov-02-23 08:00PM	Coherus BioSciences to Participate at Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-23 10:01AM	Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-30-23 06:00PM	Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire) +14.02%
05:43PM	Why Coherus BioSciences Stock Soared Today (Motley Fool)
Oct-27-23 03:07PM	Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (GlobeNewswire)
Oct-24-23 07:41PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Oct-14-23 12:30PM	Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-11-23 10:42AM	Load Up, Says Citigroup, About These 2 Strong Buy Stocks (TipRanks)
Oct-09-23 09:49AM	Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody (Zacks)
Oct-05-23 04:45PM	Why Coherus BioSciences Stock Popped Today (Motley Fool) +9.46%
08:30AM	Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA ONBODY (GlobeNewswire)
Oct-04-23 08:30AM	CIMERLI (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch (GlobeNewswire) -5.37%
Oct-02-23 09:00AM	Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day (GlobeNewswire)
Sep-27-23 09:10AM	Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Sep-26-23 10:53AM	Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down (Zacks)
Sep-25-23 08:30AM	FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections (GlobeNewswire) -9.19%
Sep-22-23 09:00PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) +7.73%
Sep-08-23 09:05AM	Coherus Completes Surface Oncology Acquisition (GlobeNewswire)
08:31AM	Why Coherus BioSciences Stock Was Plunging This Week (Motley Fool)
Sep-01-23 06:51PM	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
04:01PM	Coherus BioSciences to Participate at Upcoming September Investor Conferences (GlobeNewswire)
Aug-31-23 04:01PM	Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote FOR the Proposed Merger with Coherus BioSciences (GlobeNewswire)
Aug-22-23 05:35PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Aug-03-23 07:43PM	Why Coherus BioSciences Stock Popped Today (Motley Fool) +17.74%
Aug-02-23 05:15PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q2 Earnings Snapshot (AP Finance)
04:01PM	Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jul-26-23 04:05PM	Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023 (GlobeNewswire)
Jul-21-23 05:30PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Jul-20-23 04:04PM	Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors (GlobeNewswire)
Jul-13-23 08:30AM	Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY (GlobeNewswire)
Jul-03-23 08:52AM	UPDATE 1-Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira (Reuters)
08:30AM	Coherus Launches YUSIMRY, a Biosimilar of Humira®, at $995 per Carton in U.S. (GlobeNewswire)
Jun-26-23 09:08PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Jun-21-23 08:00PM	CHRS: Rating decreased to a SELL (Argus Research)
Jun-16-23 10:00AM	Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M (Benzinga) -23.38%
08:30AM	This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy? (Motley Fool)
07:01AM	Coherus to Acquire Surface Oncology (GlobeNewswire)
Jun-15-23 01:24PM	AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry (Benzinga)
10:49AM	UPDATE 1-Coherus resolves part of dispute with AbbVie over Humira biosimilar (Reuters)
07:07AM	Abbvie, Coherus agree to resolve dispute over Humira biosimilar (Reuters)
Jun-06-23 01:34PM	Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients (Benzinga) +5.82%
Jun-05-23 05:30PM	Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma (GlobeNewswire) +11.91%
09:46AM	Even Mark Cuban Cant Fix This Broken Drug System (The Wall Street Journal)
Jun-01-23 09:37AM	UPDATE 2-Coherus BioSciences to launch Humira biosimilar at 85% discount (Reuters)
09:07AM	Coherus BioSciences to launch Humira biosimilar at $995 per carton (Reuters)

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wahlstrom Mats	Director	Feb 01 '24	Option Exercise	1.67	59,988	100,000	99,988	Feb 05 07:03 PM
Lanfear Dennis M	President & CEO	Nov 22 '23	Option Exercise	1.42	299,940	425,015	954,793	Nov 24 04:04 PM
Lanfear Dennis M	President & CEO	Nov 22 '23	Sale	2.02	223,100	449,770	731,693	Nov 24 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CHRS

Coherus Biosciences Inc

Upgrade your FINVIZ experience